Literature DB >> 18617186

Sex hormone receptor gene variation associated with phenotype in male hypertrophic cardiomyopathy patients.

Joanne M Lind1, Christine Chiu, Jodie Ingles, Laura Yeates, Stephen E Humphries, Alison K Heather, Christopher Semsarian.   

Abstract

Hypertrophic cardiomyopathy (HCM) is a clinically heterogeneous disease, which suggests that a number of factors exist which modify disease outcome. Gender may be one such factor as more males present with the disease compared with females. The aim of the present study was to determine if an association exists between genetic variation in sex hormone receptors and the development of left ventricular hypertrophy in HCM. The study population included 200 unrelated individuals from an Australian HCM cohort. Clinical evaluation was performed. Genetic analysis of the androgen receptor (AR), estrogen receptor 1 (ESR1), estrogen receptor 2 (ESR2), and aromatase (CYP19A1) genes, was carried out in all patients. Fewer (CAG)n repeats within the AR gene were significantly associated with higher maximal left ventricular wall thickness (LVWT) in males (P=0.008), adjusting for age. Male carriers of the A allele at SNP rs6915267, located in the promoter region of ESR1, had an 11% decrease in mean LVWT compared to male GG homozygotes (P=0.047). We report for the first time that variation at the AR gene is associated with left ventricular hypertrophy in males with HCM. Understanding the impact of sex hormones on phenotype will be helpful in the risk stratification and clinical management of HCM patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18617186     DOI: 10.1016/j.yjmcc.2008.05.016

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  20 in total

Review 1.  A new era in clinical genetic testing for hypertrophic cardiomyopathy.

Authors:  Matthew Wheeler; Aleksandra Pavlovic; Emil DeGoma; Heidi Salisbury; Colleen Brown; Euan A Ashley
Journal:  J Cardiovasc Transl Res       Date:  2009-10-30       Impact factor: 4.132

Review 2.  Doping with anabolic androgenic steroids (AAS): Adverse effects on non-reproductive organs and functions.

Authors:  Eberhard Nieschlag; Elena Vorona
Journal:  Rev Endocr Metab Disord       Date:  2015-09       Impact factor: 6.514

Review 3.  Precision medicine approach to genetic cardiomyopathy.

Authors:  K Filonenko; H A Katus; B Meder
Journal:  Herz       Date:  2017-08       Impact factor: 1.443

4.  [Clinical and genetic aspects of hypertrophic and dilated cardiomyopathy].

Authors:  B Meder; H A Katus
Journal:  Internist (Berl)       Date:  2012-04       Impact factor: 0.743

5.  5'RNA-Seq identifies Fhl1 as a genetic modifier in cardiomyopathy.

Authors:  Danos C Christodoulou; Hiroko Wakimoto; Kenji Onoue; Seda Eminaga; Joshua M Gorham; Steve R DePalma; Daniel S Herman; Polakit Teekakirikul; David A Conner; David M McKean; Andrea A Domenighetti; Anton Aboukhalil; Stephen Chang; Gyan Srivastava; Barbara McDonough; Philip L De Jager; Ju Chen; Martha L Bulyk; Jochen D Muehlschlegel; Christine E Seidman; J G Seidman
Journal:  J Clin Invest       Date:  2014-02-10       Impact factor: 14.808

Review 6.  Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals.

Authors:  Farbod Sedaghat-Hamedani; Elham Kayvanpour; Oguz Firat Tugrul; Alan Lai; Ali Amr; Jan Haas; Tanja Proctor; Philipp Ehlermann; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2017-08-24       Impact factor: 5.460

Review 7.  Sarcomere gene mutations in hypertrophy and heart failure.

Authors:  Hiroyuki Morita; Ryozo Nagai; J G Seidman; Christine E Seidman
Journal:  J Cardiovasc Transl Res       Date:  2010-05-25       Impact factor: 4.132

8.  The role of renin-angiotensin-aldosterone system polymorphisms in phenotypic expression of MYBPC3-related hypertrophic cardiomyopathy.

Authors:  Iris C R M Kolder; Michelle Michels; Imke Christiaans; Folkert J Ten Cate; Danielle Majoor-Krakauer; Alexander H J Danser; Robert H Lekanne Deprez; Michael W T Tanck; Arthur A M Wilde; Connie R Bezzina; Dennis Dooijes
Journal:  Eur J Hum Genet       Date:  2012-05-09       Impact factor: 4.246

9.  Women with hypertrophic cardiomyopathy have worse survival.

Authors:  Jeffrey B Geske; Kevin C Ong; Konstantinos C Siontis; Virginia B Hebl; Michael J Ackerman; David O Hodge; Virginia M Miller; Rick A Nishimura; Jae K Oh; Hartzell V Schaff; Bernard J Gersh; Steve R Ommen
Journal:  Eur Heart J       Date:  2017-12-07       Impact factor: 29.983

10.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.